 CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 GLOBE NEWSWIRE -- Centogene N.V. Nasdaq: CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, and Alnylam Pharmaceuticals, Inc. Alnylam, the leading RNAi therapeutics company, announced today the launch of a new joint clinical screening program: the genetic screening of the at-risk population for hereditary T ransthy R etin-related AM yloidosis and longitudinal moni toring of TTR positive subjects the TRAMmoni TTR S tudy. 